Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Trane Technologies | TSMC | Tempus AI | |
|---|---|---|---|
| Moat rating | narrow Trane's FY2025 Form 10-K (filed 5 February 2026) makes exactly one rank claim about itself and it is hedged: 'We are one of the leading manufacturers in the world of HVAC systems and services and transport temperature control products and services'. It sits inside a Competitive Conditions section that opens 'Our products and services are sold in highly competitive markets throughout the world', describes 'a wide variety of competitors that vary by product line and services' including 'well-established regional or specialized competitors, as well as larger U.S. and non-U.S. corporations or divisions of larger companies', and names price first among 'the principal methods of competition in these markets', ahead of quality, delivery, service and support, technology and innovation. The risk factors push the same way: 'The markets that we serve are highly competitive', 'consolidation and new entrants (including non-traditional competitors) within our industries' 'could result in increased competition and pricing pressures', Trane competes 'with large companies and with smaller, local operators who may have customer, regulatory or economic advantages in the geographies in which they are located', and 'some of our competitors may employ pricing and other strategies that are not traditional'. What the filing does evidence is an advantage that gets paid for: 2025 net revenues of $21,321.9 million, up 7.5% from $19,838.2 million, of which the company's own bridge assigns 3.0 points to pricing; gross margin up 50 basis points to 36.2%; operating income of $3,967.4 million, 18.6% of revenues; and firm backlog up to $7,769.4 million from $6,747.7 million. But that advantage is not uniform in the same document: the EMEA pricing component was (0.3)% and its segment adjusted EBITDA margin fell 150 basis points to 18.3%, and Asia Pacific organic revenue fell 2.5% on 'lower volumes in China'. A position the company itself will only call 'one of the leading', defended in markets it calls highly competitive and priced unevenly across its three segments, is protection that is real but bounded. | wide TSMC's 2025 Form 20-F reports a 59.9% gross margin (up from 56.1% in 2024) and describes the company as "the technology leader among the dedicated foundries" in advanced (7-nanometer-and-below) node revenue — a durable, hard-to-replicate process-and-scale advantage that rivals with "greater financial and other resources" have not matched. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | switching costs The filing rules out the obvious alternative in its own words. Item 1's Patents and Licenses paragraph says the Company 'does not consider any single patent, trademark, copyright, trade secret, proprietary technology, technical data, business process or any other confidential information (or any related group of any such items) to be of material importance to any segment or to the business as a whole', and the matching risk factor is blunter: 'we do not believe that our business is materially dependent on a single intellectual property right or any group of them. In our opinion, engineering, production skills and experience are more responsible for our market position than our patents and/or licenses.' That is a company disclaiming an IP moat. Where the 10-K does locate durability is the installed equipment and the channel wrapped around it. The overview frames the entire growth plan that way - 'As an industry leader with an extensive global install base, our growth strategy includes expanding recurring revenue through services and rental options' - the principal products and services table carries 'Service agreements', 'Repair and maintenance services', 'Parts and supplies (aftermarket and OEM)' and 'Rental services' alongside the equipment itself, the Distribution paragraph puts U.S. sales through Trane's own 'branch sales offices, distributors and dealers across the country' and non-U.S. sales through 'numerous subsidiary sales and service companies with a supporting chain of distributors throughout the world', and the accounting policy confirms the contracts are multi-period: 'For extended warranties and long-term service agreements, revenue for these distinct performance obligations are recognized over time on a straight-line basis over the respective contract term.' Long-lived equipment serviced under term agreements by the manufacturer's own branches is the asset this filing keeps pointing at, which is why the moat is read as an installed-base tie rather than a patent estate. | intangibles ip Per its 2025 Form 20-F, TSMC "compete[s] primarily on process technologies, manufacturing excellence, customer trust and service quality" and has "been issued a substantial number of patents," with 2-nanometer in volume production in 2025 and 16-angstrom risk production targeted for 2026 — proprietary process-technology know-how and IP, not merely capital (the filing explicitly notes some competitors may have greater financial resources yet still trail), are the core barrier. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | co leader The company's own claim is comparative but never exclusive: 'We are one of the leading manufacturers in the world of HVAC systems and services and transport temperature control products and services' - one of, with no rank, no share figure and no competitor named anywhere in the filing. Competitive Conditions sets that against 'well-established regional or specialized competitors, as well as larger U.S. and non-U.S. corporations or divisions of larger companies', and the risk factors add that Trane competes 'with large companies and with smaller, local operators who may have customer, regulatory or economic advantages in the geographies in which they are located'. The scale behind the claim is substantial and disclosed - $21,321.9 million of 2025 net revenues, products sold in approximately 100 countries, backlog of $7,769.4 million - but the 10-K never asserts the top position in any market it serves. | clear leader Self-described in its 2025 20-F as "the technology leader among the dedicated foundries" in net revenue of advanced semiconductors at 7-nanometer and below; reached 2nm volume production in 2025, and Epoch AI estimates ~90% share of global advanced-node fabrication. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | moderate Price is a separately disclosed component of growth in this filing and it is positive: of the 7.5% increase in 2025 net revenues, the company's bridge assigns 3.0% to pricing against 3.2% volume, 0.8% acquisitions and 0.5% currency, and gross margin rose 50 basis points to 36.2% 'primarily due to gross productivity and price realization, partially offset by inflation'. In the Americas the price component was 3.8% of an 8.0% revenue increase, and that segment's adjusted EBITDA margin rose 70 basis points to 21.6% 'primarily due to price realization and gross productivity, partially offset by inflation and continued business reinvestment'. What holds the band below strong is in the same bridge and the same risk factors: EMEA pricing was (0.3)% and its segment margin fell 150 basis points to 18.3%; Asia Pacific pricing was 0.4% on organic revenue down 2.5%; consolidation and new entrants 'could result in increased competition and pricing pressures'; and 'in the event there is deflation, we may experience pressure from our customers to reduce prices.' Price that sticks in the Americas, disappears in EMEA and is disclaimed as durable in the risk factors is moderate rather than strong. | strong 2025 gross margin of 59.9% (up from 56.1% in 2024), attributed in the 20-F to higher capacity utilization and cost improvement, reflects strong pricing power at the leading edge despite the heavy capital intensity of new-node ramps. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | Trane Technologies is the Trane and Thermo King equipment maker - the FY2025 10-K opens by calling it 'a global climate innovator' selling HVAC, transport refrigeration and custom refrigeration through 'our strategic brands, Trane® and Thermo King®' - organised in three regional segments that produced 2025 net revenues of $17,168.8 million (Americas), $2,802.1 million (EMEA) and $1,351.0 million (Asia Pacific), with 'Approximately 25% of our net revenues in 2025 ... derived outside the U.S.' across 'approximately 100 countries' and 'no single external customer that accounted for more than 10% of our consolidated net revenues in 2025, 2024 or 2023'. The filing is candid that the markets are contested and equally candid that its position does not rest on intellectual property: 'engineering, production skills and experience are more responsible for our market position than our patents and/or licenses.' The durable asset it does describe is the installed base and the aftermarket attached to it - an 'extensive global install base' whose monetisation through 'services and rental options' is the stated growth strategy, reached through branch sales offices, dealers and distributors, with service agreements, repair and maintenance, aftermarket and OEM parts and rental all listed among the principal products. The 2025 financials carry that signature: revenues up 7.5% to $21,321.9 million split 3.2 points volume, 3.0 points price, 0.8 points acquisitions and 0.5 points currency; gross margin up 50 basis points to 36.2% 'primarily due to gross productivity and price realization, partially offset by inflation'; and backlog of $7,769.4 million on equipment where 'orders for specialized equipment or specific customer applications are submitted with extended lead times'. The limits are in the same filing. Price contributed 3.8% in the Americas but (0.3)% in EMEA and 0.4% in Asia Pacific; EMEA's segment adjusted EBITDA margin fell 150 basis points to 18.3%; Asia Pacific organic revenue fell 2.5% on 'lower volumes in China'; the Americas' otherwise strong year was 'partially offset by weaker volume in our Residential business'; and the risk factors warn that refrigerant regulation 'could make some of our existing HVAC and refrigeration products non-compliant or obsolete', with the company 'developing and selling our next generation products that utilize lower global warming potential solutions' against $347.6 million of 2025 research and development spending. For the AI build-out specifically, the link exists in the filing but is unsized: 'Data center HVAC systems', 'Data center liquid cooling solutions', 'Data center facility controls' and 'Data center services' appear in the principal products and services table, and those four entries are the only places the phrase occurs anywhere in the 10-K - no revenue, no ranking, no share, and no mention at all in the MD&A discussion of 2025 growth. | TSMC is the world's largest dedicated semiconductor foundry and, per its 2025 Form 20-F, the self-described technology leader among dedicated foundries in advanced (7nm-and-below) node revenue, having reached 2-nanometer volume production in 2025 with 16-angstrom risk production on track for 2026. Independent research (Epoch AI) estimates it controls roughly 90% of global advanced-node fabrication; sustained by US$7.9 billion of 2025 R&D, a large patent portfolio and 59.9% gross margins, this process-technology and scale advantage has proven durable even against rivals with greater financial resources. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | Trane sits on the facility side of the AI build-out rather than in the compute stack. Its FY2025 10-K lists 'Data center HVAC systems', 'Data center liquid cooling solutions', 'Data center facility controls' and 'Data center services' among its principal products and services, alongside 'Thermal energy storage' and 'Smart and AI-enabled services'. Those four entries are the only occurrences of the phrase in the entire filing: there is no data center revenue figure, no ranking, no named competitor and no separate reporting - segment disclosure stops at Americas, EMEA and Asia Pacific, and the MD&A attributes the Americas' 7.4% organic growth to 'realization of price increases and higher volumes led by strong demand within our Commercial HVAC business' without naming an end market. | The critical leading-edge fabrication and advanced-packaging (CoWoS) layer of the AI supply chain — high-performance computing was 58% of TSMC's 2025 revenue, and it supplies leading-edge N2/N3/N4 logic to the fabless IC-design and system companies that design AI accelerators. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.42 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |